Zacks: Chiasma, Inc. (CHMA) Given $2.50 Average Target Price by Analysts

Shares of Chiasma, Inc. (NASDAQ:CHMA) have received an average broker rating score of 5.00 (Strong Sell) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong sell recommendation.

Analysts have set a 1-year consensus price target of $2.50 for the company, according to Zacks. Zacks has also given Chiasma an industry rank of 109 out of 265 based on the ratings given to its competitors.

Separately, ValuEngine upgraded Chiasma from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.

Shares of Chiasma (NASDAQ CHMA) traded down $0.06 on Friday, reaching $1.74. 120,900 shares of the company’s stock were exchanged, compared to its average volume of 83,955. Chiasma has a 1-year low of $1.25 and a 1-year high of $2.95.

In related news, Director Scott Minick acquired 25,000 shares of Chiasma stock in a transaction dated Thursday, September 21st. The stock was purchased at an average cost of $2.37 per share, for a total transaction of $59,250.00. The purchase was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 3.80% of the company’s stock.

An institutional investor recently bought a new position in Chiasma stock. Dimensional Fund Advisors LP acquired a new position in Chiasma, Inc. (NASDAQ:CHMA) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 53,481 shares of the biotechnology company’s stock, valued at approximately $136,000. Dimensional Fund Advisors LP owned approximately 0.22% of Chiasma at the end of the most recent reporting period. Institutional investors and hedge funds own 54.56% of the company’s stock.

WARNING: “Zacks: Chiasma, Inc. (CHMA) Given $2.50 Average Target Price by Analysts” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://sportsperspectives.com/2017/12/19/zacks-chiasma-inc-chma-given-2-50-average-target-price-by-analysts.html.

Chiasma Company Profile

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

Get a free copy of the Zacks research report on Chiasma (CHMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply